Basic Science: Bone Metastases: The Molecular Basis of Skeletal Metastases

Clinical Orthopaedics and Related Research

Volumn 415, Issue SUPPL., 2003, Pages

  Choong, Peter F M ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; CADHERIN; GROWTH FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN; INTEGRIN; LIGAND; METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR; SELECTIN; UROKINASE;

BIOCHEMISTRY; BONE METASTASIS; BONE PAIN; CANCER THERAPY; CELL ADHESION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONFERENCE PAPER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0142188118     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000093839.72468.da     Document Type: Conference Paper

References (141)

1. Aigner A, Renneberg H, Bojunga J, et al: Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 21:5:733-5742, 2002.
2. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN: Plasminogen activator inhibitors: Hormonally regulated serpins. Mol Cell Endocrinol 68:1-19, 1990.
3. Banks RE, Gearing AJ, Hemingway IK, et al: Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-I (VCAM-1) in human malignancies. Br J Cancer 68:122-124, 1993.
4. Bargatze RF, Wu NW, Weissman IL, Butcher EC: High endothelial venule binding as a predictor of the dissemination of passaged murine lymphomas. J Exp Med 166:1125-1131, 1987.
5. Barnes J, Anthony CT, Wall N, Steiner MS: Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 13:337-343,1995.
6. Batson OV: The function of the certebral veins and their role in the spread of metastases. Arch Surg 112:138-149, 1940.
7. Behrens J, Frixen U, Schipper J, Weidner M, Birchmeier W: Cell adhesion in invasion and metastasis. Semin Cell Biol 3:169-178, 1992.
8. Behrens J, Mareel MM, Van Roy FM, Birchmeier W: Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108:2435-2447, 1989.
9. Behrens J, von Kries JP, Kuhl M, et al: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:638-642, 1996.
10. Behrens J, Weidner KM, Frixen UH, et al: The role of E-cadherin and scatter factor in tumor invasion and cell motility. EXS 59:109-126, 1991.
11. Bentley H, Hamdy FC, Hart KA, et al: Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 66:1159-1163, 1992.
12. Bevilacqua M, Butcher E, Furie B, et al: Selectins: A family of adhesion receptors. Cell 67:233, 1991.
13. Bevilacqua MP: Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11:767-804, 1993.
14. Bhargava M, Joseph A, Knesel J, et al: Scatter factor and hepatocyte growth factor: Activities, properties, and mechanism. Cell Growth Differ 3:11-20, 1992.
15. Birchmeier W, Behrens J: Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198:11-26, 1994.
16. Blasi F, Carmeliet P: uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943, 2002.
17. Boyer B, Valles A, Thiery J: Model systems of carcinoma cell dispersion. Curr Top Microbiol Immunol 213:179-194, 1996.
18. Brooks PC, Montgomery AM, Rosenfeld M, et al: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994.
19. Brown JM, Corey E, Lee ZD, et al: Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611-616, 2001.
20. Chambers A, Groom A, MacDonald I: Dissemination and growth of cancer cells in metastatic sites. Nature Rev 2:563-572, 2002.
21. Cooper CR, Bhatia JK, Muenchen HJ, et al: The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clin Exp Metastasis 19:25-33, 2002.
22. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. Embo J 9:1079-1085, 1990.
23. Curtis E, Krech R, Walsh T: Common symptoms in patients with advanced cancers. J Palliat Care 7:25-29, 1991.
24. Dedhar S: Regulation of expression of the cell adhesion receptors, integrins, by recombinant human interleukin-1 beta in human osteosarcoma cells: Inhibition of cell proliferation and stimulation of alkaline phosphatase activity. J Cell Physiol 138:291-299, 1989.
25. Duffy MJ: Urokinase-type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem Soc Trans 30:207-210, 2002.
26. Elliott B, Ostman A, Westermark B, Rubin K: Modulation of growth factor responsiveness of murine mammary carcinoma cells by cell matrix interactions: Correlation of cell proliferation and spreading. J Cell Physiol 152:292-301, 1992.
27. Festuccia C, Angelucci A, Gravina G, et al: Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement. Exp Cell Res 280:1-11, 2002.
28. Frixen UH, Behrens J, Sachs M, et al: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113:173-185, 1991.
29. Furstenberger G, Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 3:298-302, 2002.
30. Garcia de Galdeano A, Cruz-Conde JC, Boyano MD, Garcia-Vazquez MD, Canavate ML: Effect of IL-2 and IL-6 on parameters related to metastatic activity in a murine melanoma. Pathobiology 69:230-236, 2001.
31. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51:3753-3761, 1991.
32. Goltzman D, Bolivar I, Rabbani SA: Studies on the pathogenesis of osteoblastic metastases by prostate cancer. Adv Exp Med Biol 324:165-171, 1992.
33. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74:111-122, 1997.
34. Gruber R, Varga F, Fischer MB, Watzek G: Platelets stimulate proliferation of bone cells: Involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res 13:529-535, 2002.
35. Gruss HJ, Dolken G, Brach MA, Mertelsmann R, Herrmann F: Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. Leukemia 7:1245-1249, 1993.
36. Gui GP, Wells CA, Yeomans P, et al: Integrin expression in breast cancer cytology: A novel predictor of axillary metastasis. Eur J Surg Oncol 22:254-258, 1996.
37. Guise TA, Yin JJ, Mohammad KS: Role of endothelin-1 in osteoblastic bone metastases. Cancer 97:779-784, 2003.
38. Guise TA, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549, 1996.
39. Guise TA, Yin JJ, Thomas RJ, et al: Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 30:670-676, 2002.
40. Gunthert U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13-24, 1991.
41. Haq M, Goltzman D, Tremblay G, Brodt P: Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 52:4613-4619, 1992.
42. Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K: Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 80:459-463, 1989.
43. Heider KH, Hofmann M, Hors E, et al: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120:227-233, 1993.
44. Heino J, Massague J: Transforming growth factor-beta switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. J Biol Chem 264:21806-21811, 1989.
45. Hemler ME: VLA proteins in the integrin family: Structures, functions, and their role on leukocytes. Annu Rev Immunol 8:365-400, 1990.
46. Hofbauer LC, Neubauer A, Heufelder AE: Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92:460-470, 2001.
47. Hofmann M, Rudy W, Zoller M, et al: CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res 51:5292-5297, 1991.
48. Horwitz A, Duggan K, Buck C, Beckerle MC, Burridge K: Interaction of plasma membrane fibronectin receptor with talin A transmembrane link-age. Nature 320:531-533, 1986.
49. Hulsken J, Birchmeier W, Behrens J: E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol 127:2061-2069, 1994.
50. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11-25, 1992.
51. Ishida A, Fujita N, Kitazawa R, Tsuruo T: Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J Biol Chem 277:26217-26224, 2002.
52. Johnson JP: Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev 10:11-22, 1991.
53. Juneja HS, Schmalsteig FC, Lee S, Chen J: Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Exp Hematol 21:444-450, 1993.
54. Kakonen SM, Selander KS, Chirgwin JM, et al: Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277:24571-24578, 2002.
55. Keller ET: The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 38:91-102, 2002.
56. Keller ET, Zhang J, Cooper CR, et al: Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Rev 20:333-349, 2001.
57. Kiriyama T, Gillespie MT, Glatz JA, et al: Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): A paracrine regulator? Mol Cell Endocrinol 92:55-62, 1993.
58. Kitamura Y, Morita I, Nihei Z, Mishima Y, Murota S: Effect of IL-6 on tumor cell invasion of vascular endothelial monolayers. Surg Today 27:534-541, 1997.
59. Kitazawa S, Kitazawa R: RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228-236, 2002.
60. Kohn E, Francis E, Liotta L, Schiffmann E: Heterogeneity of the motility responses in malignant tumor cells: A biological basis for the diversity and homing of metastatic cells. Int J Cancer 46:287-292, 1990.
61. Konety BR, Nelson JB: Nonandrogenic mediators of prostatic growth. Hematol Oncol Clin North Am 15:459-476, 2001.
62. Koretz K, Schlag P, Boumsell L, Moller P: Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 138:741-750, 1991.
63. Korinek V, Barker N, Morin PJ, et al: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784-1787, 1997.
64. Kostenuik PJ, Shalhoub V: Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613-635, 2001.
65. Kostenuik PJ, Singh G, Suyama KL, Orr FW: A quantitative model for spontaneous bone metastasis: Evidence for a mitogenic effect of bone on Walker 256 cancer cells. Clin Exp Metastasis 10:403-410, 1992.
66. Koukoulis GK, Virtanen I, Korhonen M, et al: Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast: Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 139:787-799, 1991.
67. Krause T, Turner GA: Are selectins involved in metastasis? Clin Exp Metastasis 17:183-192, 1999.
68. Lamm ML, Podlasek CA, Barnett DH, et al: Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate. Dev Biol 232:301-314, 2001.
69. Landis S, Murray T, Bolden S, Wingo P: Cancer statistics. CA Cancer J Clin 48:6-29, 1998.
70. Lazar-Molnar E, Hegyesi H, Toth S, Falus A: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12:547-554, 2000.
71. Le Brun G, Aubin P, Soliman H, et al: Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 11:157-162, 1999.
72. Lijnen HR, De Cock F, Collen D: Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. Eur J Biochem 224:567-574, 1994.
73. Lin DL, Tarnowski CP, Zhang J, et al: Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47:212-221, 2001.
74. Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68, 1980.
75. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729-3735, 2002.
76. MacDougall JR, Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14:351-362, 1995.
77. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E: Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18-24, 2001.
78. Mareel MM, Behrens J, Birchmeier W, et al: Down-regulation of E-cadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer 47:922-928, 1991.
79. Masuda H, Fukabori Y, Nakano K, et al: Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54:268-274, 2003.
80. Matrisian LM, Hogan BL: Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr Top Dev Biol 24:219-259, 1990.
81. Matsumura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340:1053-1058, 1992.
82. Mauviel A: Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 53:288-295, 1993.
83. Mbalaviele G, Dunstan CR, Sasaki A, et al: E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56:4063-4070, 1996.
84. McEver RP: Selectins: Novel receptors that mediate leukocyte adhesion during inflammation. Thromb Haemost 65:223-228, 1991.
85. Meiners S, Brinkmann V, Naundorf H, Birchmeier W: Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene 16:9-20, 1998.
86. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K: Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61:1637-1644, 2001.
87. Miles LA, Levin EG, Plescia J, Collen D, Plow EF: Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. Blood 72:628-635, 1988.
88. Mirels H: Metastatic disease of long bones: A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop 249:256-264, 1989.
89. Molenaar M, van de Wetering M, Oosterwegel M, et al: XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86:391-399, 1996.
90. Mondino A, Resnati M, Blasi F: Structure and function of the urokinase receptor. Thromb Haemost (82 Suppl 1):19-22, 1999.
91. Morin PJ, Sparks AB, Korinek V, et al: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787-1790, 1997.
92. Mortarini R, Anichini A, Parmiani G: Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins. Int J Cancer 47:551-559, 1991.
93. Moustakas A, Pardali K, Gaal A, Heldin CH: Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82:85-91, 2002.
94. Mulligan MS, Till GO, Smith CW, et al: Role of leukocyte adhesion molecules in lung and dermal vascular injury after thermal trauma of skin. Am J Pathol 144:1008-1015, 1994.
95. Mundy G: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Rev 2:584-593, 2002.
96. Nakanishi Y, Ochiai A, Akimoto S, et al: Expression of E-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: Immunohistochemical analysis of 96 lesions. Oncology 54:158-165, 1997.
97. Natali P, Nicotra MR, Cavaliere R, et al: Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 50:1271-1278, 1990.
98. Nelson JB, Chan-Tack K, Hedican SP, et al: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663-668, 1996.
99. Nelson JB, Hedican SP, George DJ, et al: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949, 1995.
100. Nelson JB, Nguyen SH, Wu-Wong JR, et al: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53:1063-1069, 1999.
101. Noujaim D, van Golen CM, van Golen KL, Grauman A, Feldman EL: N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. Oncogene 21:4549-4557, 2002.
102. Okada T, Hawley RG, Kodaka M, Okuno H: Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model. Clin Exp Metastasis 17:623-629, 1999.
103. Orr FW, Buchanan MR, Tron VA, et al: Chemotactic activity of endothelial cell-derived interleukin 1 for human tumor cells. Cancer Res 48:6758-6763, 1988.
104. Orui H, Imaizumi S, Ogino T, Motoyama T: Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: A preliminary report. J Orthop Sci 5:600-604, 2000.
105. Osborn L: Leukocyte adhesion to endothelium in inflammation. Cell 62:3-6, 1990.
106. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1:571-573, 1889.
107. Payne R: Mechanisms and management of bone pain. Cancer 80(Suppl 8):1608-1613, 1997.
108. Pepper M, Matsumoto K, Nakamura T, Orci L, Montesano R: Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 267:20493-20496, 1992.
109. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392:190-193, 1998.
110. Petersen LC, Lund LR, Nielsen LS, Dano K, Skriver L: One-chain urokinase plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 263:11189-11195, 1988.
111. Pignatelli M, Smith ME, Bodmer WF: Low expression of collagen receptors in moderate and poorly differentiated colorectal adenocarcinomas. Br J Cancer 61:636-638, 1990.
112. Ploug M, Behrendt N, Lober D, Dano K: Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost 17:183-193, 1991.
113. Ploug M, Ronne E, Behrendt N, et al: Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266:1926-1933, 1991.
114. Polette M, Birembaut P: Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30:1195-1202, 1998.
115. Powell GJ, Southby J, Danks JA, et al: Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res 51:3059-3061, 1991.
116. Rabbani SA, Desjardins J, Bell AW, et al: An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 173:1058-1064, 1990.
117. Robertson TE, Nikolic-Paterson DJ, Hurst LA, Atkins RC, Chadban SJ: IL-10 induces mesangial cell proliferation via a PDGF-dependent mechanism. Clin Exp Immunol 130:241-244, 2002.
118. Roussel E, Gingras MC, Ro JY, Branch C, Roth JA: Loss of alpha 1 beta 1 and reduced expression of other beta 1 integrins and CAM in lung adenocarcinoma compared with pneumocytes. J Surg Oncol 56:198-208, 1994.
119. Sanchez-Sweatman OH, Orr FW, Singh G: Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 18:297-305, 1998.
120. Simpson E, Harrod J, Eilon G, Jacobs JW, Mundy GR: Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. Endocrinology 117:1615-1620, 1985.
121. Sloan EK, Anderson RL: Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci 59:1491-1502, 2002.
122. Song Z, Wu X, Powell WC, et al: Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: A new mouse model for prostatic intra-epithelial neoplasia. Cancer Res 62:5096-5105, 2002.
123. Stallmach A, von Lampe B, Matthes H, Bornhoft G, Riec-ken EO: Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. Gut 33:342-346, 1992.
124. Stoker M, Gherardi E, Perryman M, Gray J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239-242, 1987.
125. Stracke M, Krutzsch H, Unsworth E, et al: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267:2524-2529, 1992.
126. Su LK, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 262:1734-1737, 1993.
127. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451-1455, 1991.
128. Teicher BA: Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Rev 20:133-143, 2001.
129. Thomas BG, Hamdy FC: Bone morphogenetic protein-6: Potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 3:283-285, 2000.
130. Thomas RJ, Guise TA, Yin JJ, et al: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451-4458, 1999.
131. Tolcher AW, Kennedy A, Padley RJ, et al: Other novel agents: Rationale and current status as chemopreventive agents. Urology 57:86-89, 2001.
132. van der Boon J: New drug slows prostate-cancer progression. Lancet Oncol 3:201, 2002.
133. Varani J, Hattori Y, Dame MK, et al: Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue. Br J Cancer 84:1076-1083, 2001.
134. Weinel RJ, Rosendahl A, Pinschmidt E, et al: The alpha 6-integrin receptor in pancreatic carcinoma. Gastroenterology 108:523-532, 1995.
135. Weiss L, Orr FW, Honn KV: Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clin Exp Metastasis 7:127-167, 1989.
136. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75, 1997.
137. Wozney JM: Overview of bone morphogenetic proteins. Spine 27 (Suppl):S2-8, 2002.
138. Yin JJ, Selander K, Chirgwin JM, et al: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206, 1999.
139. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG: Matrix metalloproteinases: Novel targets for directed cancer therapy. Drugs Aging 11:229-244, 1997.
140. Zhang J, Dai J, Qi Y, et al: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244, 2001.
141. Zhang Z, Tarone G, Turner DC: Expression of integrin alpha 1 beta 1 is regulated by nerve growth factor and dexamethasone in PC12 cells. Functional consequences for adhesion and neurite out-growth. J Biol Chem 268:5557-5565, 1993.